New Product Launches Benefit GMED Stock Amid Macro Issues
Globus Medical currently awaits a strong cadence of product launches throughout the Musculoskeletal portfolio in the coming months of 2025.
Globus Medical (GMED) Gets a Hold from Truist Financial
In a report released today, Richard Newitter from Truist Financial maintained a Hold rating on Globus Medical (GMED – Research Report). The ...
Globus Medical price target lowered to $82 from $90 at Truist
Truist analyst Richard Newitter lowered the firm’s price target on Globus Medical (GMED) to $82 from $90 and keeps a Hold rating on the shares.
4GMED : Breaking Down Globus Medical: 5 Analysts Share Their Views
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $97.6, a high estimate of $103.00, and a low estimate of $93.00. This upward trend ...